Biotech Stocks - Directory w/ AI Reviews
Biotechnology companies develop treatments for some of medicine's most challenging diseases, from cancer and autoimmune disorders to rare genetic conditions. Regeneron and Amgen are established biopharmaceutical leaders with deep pipelines, while CRISPR Therapeutics and Moderna represent the cutting edge of gene editing and mRNA technology. Biotech stocks carry binary risk around clinical trial results but offer the potential for outsized returns when therapies succeed.
1
4.6
New
Regeneron Pharmaceuticals
REGN
$803.17
+2.49%
P/E: 32.8
Regeneron is a top-tier biotech stock powered by its industry-leading antibody discovery platform and the explosive growth of Dupixent across multiple inflammatory indications, demonstrating the kind of science-driven innovation and commercial execution that biotech investors seek.
2
4.5
New
Amgen
AMGN
$369.19
+0.82%
P/E: 22.0
Amgen is a cornerstone biotech stock representing one of the industry's most successful companies, with a deep pipeline of biologic therapies, a proven track record of bringing innovative medicines to market, and the scale to invest billions annually in research and development across multiple thera
3
4.5
New
CRISPR Therapeutics
CRSP
$53.07
+8.46%
P/E: 2.9
CRISPR Therapeutics is at the frontier of biotechnology with its gene-editing platform, having achieved the historic milestone of the first approved CRISPR-based therapy and pursuing a deep pipeline of next-generation treatments.
4
4.4
New
Gilead Sciences
GILD
$154.98
+2.09%
P/E: 17.8
Gilead Sciences is a biotech pioneer in antiviral therapies, with groundbreaking treatments for HIV and hepatitis C, and is expanding its oncology pipeline through acquisitions and internal development of cell therapies and antibody-drug conjugates.
5
3.3
New
Moderna
MRNA
$42.23
+5.29%
Moderna exemplifies the innovative potential of biotech investing, having built an entire therapeutic platform around mRNA technology that extends far beyond its landmark COVID-19 vaccine into oncology, rare diseases, and personalized medicine, offering investors exposure to what could become a foun